3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Classical hematology
1
Conditions
Myelodysplastic Syndromes
1
Anemia
1
Interventions
nilotinib
6
bosutinib
4
asciminib
3
Imatinib Mesylate
3
Decitabine
3
decitabine and cedazuridine drug combination
2
cedazuridine
2
avapritinib
2
Dasatinib
2
Cytarabine
2
Azacitidine
2
treosulfan
1
trametinib
1
tagraxofusp
1
pemigatinib
1
olutasidenib
1
luspatercept
1
ivosidenib
1
imetelstat
1
glasdegib
1
enasidenib
1
dabrafenib
1
GRN163L peptide
1
Emapalumab
1
Daunorubicin
1
Busulfan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
luspatercept
×
Myeloid
×
Clear all
NCT02631070
2021-12-17
MEDALIST
Celgene
Phase 3
Completed
229 enrolled
36 charts
1 FDA